GUTS Fractyl Health Inc

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m. ET.

A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com.

Contacts 

Media Contact Jessica Cotrone, Head of Corporate Communicationsjcotrone@fractyl.com. 978.760.5622

Investor ContactBrian Luque, Head of Investor Relations and Corporate DevelopmentIR@fractyl.com, 951.206.1200